Key statistics
As of last trade Lantheus Holdings Inc (0L8:STU) traded at 96.34, -16.04% below its 52-week high of 114.75, set on Jul 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 95.62 |
---|---|
High | 97.14 |
Low | 95.62 |
Bid | 96.36 |
Offer | 98.06 |
Previous close | 96.40 |
Average volume | 67.11 |
---|---|
Shares outstanding | 69.43m |
Free float | 67.69m |
P/E (TTM) | 17.78 |
Market cap | 7.54bn USD |
EPS (TTM) | 6.11 USD |
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
- Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
- Lantheus Appoints Julie Eastland as New Board Member
- Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
- Lantheus Reports Second Quarter 2024 Financial Results
- Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
- Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
- Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
- Lantheus Appoints Jamie Spaeth as Chief People Officer
- Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
More ▼